Wegovy (Semaglutide) for Weight Loss: Uses and Side Effects

What Wegovy Is

Wegovy is the brand name for semaglutide 2.4 mg, a once-weekly subcutaneous injection by Novo Nordisk. The FDA first approved it on June 4, 2021, as an adjunct to reduced-calorie diet and increased physical activity for chronic weight management in adults 1Ref 1Wilding JPH, Batterham RL, Calanna S, et al.; STEP 1 Study Group (2021).Once-Weekly Semaglutide in Adults with Overweight or Obesity.Primary efficacy data: −14.9% mean body weight reduction at 68 weeks; adverse reaction rates (nausea 44%, diarrhea 30%, vomiting 25%); BMI thresholds and weight-management indication studied in the pivotal trial underlying the 2021 approval. On March 8, 2024, the FDA approved a second indication for a cardiovascular benefit — the first ever granted to a weight-loss drug 6Ref 6U.S. Food and Drug Administration (2024).FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight.Regulatory approval action: on March 8, 2024 the FDA approved Wegovy (semaglutide) to reduce the risk of cardiovascular death, heart attack, and stroke in adults with cardiovascular disease and obesity or overweight — the first weight-loss drug approved for cardiovascular event reduction.

Semaglutide belongs to the GLP-1 receptor agonist class. The same molecule at a lower dose is sold as Ozempic for type 2 diabetes; Wegovy at 2.4 mg is the dedicated weight-management formulation.

Who Qualifies

The weight-management indication covers adults with:

• BMI of 30 or higher, or
• BMI of 27 or higher with at least one weight-related condition (hypertension, type 2 diabetes, or dyslipidemia) 1Ref 1Wilding JPH, Batterham RL, Calanna S, et al.; STEP 1 Study Group (2021).Once-Weekly Semaglutide in Adults with Overweight or Obesity.Primary efficacy data: −14.9% mean body weight reduction at 68 weeks; adverse reaction rates (nausea 44%, diarrhea 30%, vomiting 25%); BMI thresholds and weight-management indication studied in the pivotal trial underlying the 2021 approval.

The cardiovascular indication, approved March 8, 2024, covers adults with a BMI of 27 or higher and established cardiovascular disease — for example a prior heart attack, stroke, or peripheral artery disease 6Ref 6U.S. Food and Drug Administration (2024).FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight.Regulatory approval action: on March 8, 2024 the FDA approved Wegovy (semaglutide) to reduce the risk of cardiovascular death, heart attack, and stroke in adults with cardiovascular disease and obesity or overweight — the first weight-loss drug approved for cardiovascular event reduction. The pivotal trial behind that indication enrolled adults without a diabetes history 2Ref 2Lincoff AM, Brown-Frandsen K, Colhoun HM, et al.; SELECT Trial Investigators (2023).Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.Trial result only: 20% relative reduction in MACE (CV death, non-fatal MI, non-fatal stroke) with semaglutide 2.4 mg vs placebo in adults with established CVD and obesity but no diabetes; the regulatory approval action itself is cited to the FDA [6].

Wegovy is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or MEN 2, and is not recommended during pregnancy.

How It Works

GLP-1 is a hormone the gut naturally releases after a meal. Semaglutide mimics it and acts on three systems at once:

• Brain: Binds to GLP-1 receptors in appetite-regulating areas of the hypothalamus, reducing hunger signals and increasing the sense of fullness.
• Stomach: Slows gastric emptying, so food stays in the stomach longer — meals feel satisfying on smaller portions.
• Pancreas: Stimulates insulin secretion in a glucose-dependent manner and suppresses glucagon, helping to stabilize blood sugar even in non-diabetic patients.

Because the drug suppresses appetite through a hormonal pathway rather than through willpower alone, many people find they consume significantly less without feeling deprived — though individual response varies.

What the Evidence Shows

The STEP 1 trial — a 68-week, randomized, double-blind, placebo-controlled study of 1,961 adults with obesity or overweight but without diabetes — is the primary efficacy anchor for Wegovy:

• Mean body weight reduction: −14.9% in the semaglutide group vs. −2.4% with placebo 1Ref 1Wilding JPH, Batterham RL, Calanna S, et al.; STEP 1 Study Group (2021).Once-Weekly Semaglutide in Adults with Overweight or Obesity.Primary efficacy data: −14.9% mean body weight reduction at 68 weeks; adverse reaction rates (nausea 44%, diarrhea 30%, vomiting 25%); BMI thresholds and weight-management indication studied in the pivotal trial underlying the 2021 approval
• 86.4% of participants on semaglutide lost at least 5% of body weight, vs. 31.5% on placebo
• 50.5% lost at least 15% of body weight, vs. 4.9% on placebo
• Waist circumference fell by an average of 13.5 cm vs. 4.1 cm

The SELECT trial (NCT03574597) enrolled 17,604 adults with pre-existing cardiovascular disease and a BMI of 27 or greater but no diabetes. Over approximately 40 months, semaglutide 2.4 mg reduced the composite risk of cardiovascular death, non-fatal heart attack, or non-fatal stroke by 20% relative to placebo (6.5% vs. 8.0% absolute event rate) 2Ref 2Lincoff AM, Brown-Frandsen K, Colhoun HM, et al.; SELECT Trial Investigators (2023).Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.Trial result only: 20% relative reduction in MACE (CV death, non-fatal MI, non-fatal stroke) with semaglutide 2.4 mg vs placebo in adults with established CVD and obesity but no diabetes; the regulatory approval action itself is cited to the FDA [6]. The FDA cited this trial when it approved the cardiovascular indication on March 8, 2024 — a first for any anti-obesity medication 6Ref 6U.S. Food and Drug Administration (2024).FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight.Regulatory approval action: on March 8, 2024 the FDA approved Wegovy (semaglutide) to reduce the risk of cardiovascular death, heart attack, and stroke in adults with cardiovascular disease and obesity or overweight — the first weight-loss drug approved for cardiovascular event reduction.

Because these are the pivotal trials that led to FDA approval, the results represent the strongest available evidence for Wegovy's efficacy.

Side Effects

Gastrointestinal effects are the most common class of side effects. From the STEP 1 trial and the prescribing label 1Ref 1Wilding JPH, Batterham RL, Calanna S, et al.; STEP 1 Study Group (2021).Once-Weekly Semaglutide in Adults with Overweight or Obesity.Primary efficacy data: −14.9% mean body weight reduction at 68 weeks; adverse reaction rates (nausea 44%, diarrhea 30%, vomiting 25%); BMI thresholds and weight-management indication studied in the pivotal trial underlying the 2021 approval:

Very common (affecting more than 1 in 10 people): - Nausea — 44% on Wegovy vs. 16% on placebo - Diarrhea — 30% vs. 16% - Vomiting — 25% vs. 6% - Constipation — 24% vs. 11% - Abdominal pain — 20% vs. 10%

Overall, 73% of Wegovy-treated participants reported some gastrointestinal event, compared with 47% on placebo. Most GI effects are dose-dependent, peak during the escalation phase, and diminish over time. They are the most common reason people discontinue treatment.

Less common but important to know: - Fatigue and dizziness - Injection-site reactions (redness, bruising) - Heart rate increase of approximately 2–3 beats per minute on average - Worsening diabetic retinopathy (in patients with pre-existing eye disease and rapid blood-sugar improvement)

Rare but serious — seek immediate care: - Acute pancreatitis (discontinue and do not restart if confirmed) - Acute gallbladder disease and cholelithiasis - Acute kidney injury (often from dehydration associated with GI illness) - Severe allergic reaction (anaphylaxis, angioedema)

FDA Boxed Warning: In rodent studies, semaglutide caused thyroid C-cell tumors at clinically relevant exposures. It is unknown whether this risk applies to humans. Wegovy is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN 2.

Long-Term Use and What Happens If Wegovy Is Stopped

Wegovy is designed for long-term, chronic use. The drug suppresses appetite through a hormonal mechanism active only while it is present; stopping it allows appetite and metabolic set-point to return toward baseline.

In the STEP 1 trial extension, participants who stopped semaglutide regained a mean of 11.6 percentage points of body weight within one year — roughly two-thirds of their prior weight loss 3Ref 3Wilding JPH, Batterham RL, Davies M, et al. (2022).Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension.Mean weight regain of 11.6 percentage points (approximately two-thirds of prior losses) within one year of stopping semaglutide; supports long-term use framing. Blood pressure, lipids, and blood sugar similarly trended back toward pre-treatment values.

The STEP 4 trial confirmed the flip side: those who continued semaglutide lost a further 7.9% of body weight, while those switched to placebo gained 6.9% over 48 weeks 4Ref 4Rubino D, Abrahamsson N, Davies M, et al.; STEP 4 Investigators (2021).Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.Continued semaglutide produced further −7.9% weight loss while switchers to placebo gained +6.9% over 48 weeks — confirming that sustained treatment is required to maintain weight benefit. Clinicians typically discuss this long-term commitment — and its cost implications — before a patient starts.

Dosing Schedule

Wegovy is injected once weekly under the skin of the abdomen, thigh, or upper arm. The dose escalates gradually over 16 weeks to minimize GI side effects:

• Weeks 1–4: 0.25 mg
• Weeks 5–8: 0.5 mg
• Weeks 9–12: 1.0 mg
• Weeks 13–16: 1.7 mg
• Week 17 onward: 2.4 mg (maintenance)

If the 2.4 mg maintenance dose is not tolerated, a temporary return to 1.7 mg is an option 1Ref 1Wilding JPH, Batterham RL, Calanna S, et al.; STEP 1 Study Group (2021).Once-Weekly Semaglutide in Adults with Overweight or Obesity.Primary efficacy data: −14.9% mean body weight reduction at 68 weeks; adverse reaction rates (nausea 44%, diarrhea 30%, vomiting 25%); BMI thresholds and weight-management indication studied in the pivotal trial underlying the 2021 approval.

Cost and Coverage

Cost is one of the most significant real-world barriers to Wegovy access. Prices and savings programs change frequently, so confirm current figures with the pharmacy, the manufacturer, and your plan.

List price: Approximately $1,350 per month without insurance for the maintenance pen.

Manufacturer self-pay: Novo Nordisk offers a direct, cash-pay channel (NovoCare Pharmacy) that has typically run well below list price for patients without coverage; the exact amount varies by dose and offer period, so check the current self-pay price before ordering.

Commercially insured: A NovoCare savings card can lower out-of-pocket cost for eligible patients with commercial insurance. Government beneficiaries are excluded.

Medicare Part D: Coverage for weight loss alone was historically prohibited. The 2024 cardiovascular indication opened a pathway for Medicare patients with established heart disease and a BMI of 27 or higher; KFF estimated roughly 3.6 million Medicare beneficiaries could become eligible through that route 5Ref 5Cubanski J, Neuman T, Sroczynski N, Damico A (2024).A New Use for Wegovy Opens the Door to Medicare Coverage for Millions of People with Obesity.Medicare Part D coverage pathway for Wegovy opened via the cardiovascular indication; estimate of roughly 3.6 million potentially eligible Medicare beneficiaries. Does NOT establish the GLP-1 Bridge $50 price (that is cited to CMS [7]). Separately — and as a labeled future scenario, not a guarantee — CMS has announced the Medicare GLP-1 Bridge, a time-limited voluntary demonstration scheduled to run July 1, 2026 through December 31, 2027, under which eligible beneficiaries would pay a flat ~$50/month for certain GLP-1s, including Wegovy, used for weight management; the $50 copay would not count toward the Part D out-of-pocket cap 7Ref 7Centers for Medicare & Medicaid Services (2026).Coming Soon: CMS to Provide $50 Monthly Access to GLP-1 Medications for Medicare Beneficiaries.Announced Medicare GLP-1 Bridge: a time-limited voluntary demonstration scheduled July 1, 2026–December 31, 2027 under which eligible beneficiaries pay a flat ~$50/month for certain GLP-1s including Wegovy used for weight management; the $50 copay does not count toward the Part D out-of-pocket cap. Cited only as a labeled future scenario (Art. XV). Terms and timing are subject to change.

Prior authorization: Most plans require a clinician to document BMI thresholds and — commonly — a prior supervised weight-loss attempt of 3 to 6 months. Medicaid coverage varies by state; roughly half of state programs cover anti-obesity medications.